A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
|ClinicalTrials.gov Identifier: NCT00077610|
Recruitment Status : Completed
First Posted : February 13, 2004
Results First Posted : February 29, 2016
Last Update Posted : January 13, 2017
|Condition or disease||Intervention/treatment||Phase|
|Anemia||Drug: Epoetin alfa or beta Drug: RO0503821 (1x/2 Weeks) Drug: RO0503821 (1x/4 Weeks)||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||673 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.|
|Study Start Date :||February 2004|
|Primary Completion Date :||August 2005|
|Study Completion Date :||August 2005|
Experimental: RO0503821 (1x/2 Weeks)
Participants received RO0503821 (Mircera [methoxy polyethylene glycol-epoetin beta]) once every two weeks intravenously for 52 weeks. Participants received a starting dose of RO0503821 (60, 100, or 180 microgram [mcg]) that was based on the Epoetin dose (<8000, 8000-16000, >16000 International units [IU]/Week) administered during the week preceding the switch to the study drug.
Drug: RO0503821 (1x/2 Weeks)
60, 100, or 180 microgram (mcg) (starting dose) once every two weeks intravenously for 52 weeks.
Other Name: Mircera
Experimental: RO0503821 (1x/4 Weeks)
Participants received RO0503821 once every four weeks intravenously for 52 weeks. Participants received a starting dose of RO0503821 (120, 200, or 360 mcg) that was based on the Epoetin dose (<8000, 8000-16000, >16000 IU/Week) administered during the week preceding the switch to the study drug.
Drug: RO0503821 (1x/4 Weeks)
120, 200 or 360 mcg (starting dose) once every four weeks intravenously for 52 weeks.
Other Name: Mircera
Active Comparator: Epoetin (1-3x/Weeks)
Participants received their ongoing weekly intravenous dose of Epoetin alfa or beta one, two or three times weekly for 52 weeks.
Drug: Epoetin alfa or beta
intravenously 3 times weekly for 52 weeks, as prescribed
Other Name: Epoetin
- Mean Change in Hemoglobin (Hb) Concentration From Baseline to Evaluation Period [ Time Frame: Baseline, Week 29 to Week 36 ]A time adjusted mean change in Hb concentration was calculated using an Area Under the Curve (AUC) approach, for both periods separately. Change in Hb concentration between the Baseline and evaluation periods was calculated by subtracting the calculated average baseline Hb from the average evaluation period Hb. At the end of the Week 36, data allowing the evaluation of the therapeutic response was available for 188 out of 221 eligible participants in RO0503821 (1x/2 Weeks) arm; 172 out of 220 eligible participants in RO0503821 (1x/4 Weeks); and 180 out of 225 participants in Epoetin (1-3x/Weeks) arm.
- Number of Participants Maintaining Average Hemoglobin Concentration During Evaluation Period Within +/- 1 Gram Per Deciliter (g/dl) of Average Baseline Hemoglobin Concentration. [ Time Frame: Baseline, Week 29 to Week 36 ]The mean Hb of all values recorded during the evaluation period were calculated, and were subtracted from the mean baseline Hb for each participant. The number of participants maintaining their average Hb within +/- 1 g/dL of their average baseline hemoglobin concentration is given.
- The Incidence of Red Blood Cell (RBC) Transfusions During the Titration and Evaluation Periods [ Time Frame: Week 1 to Week 36 ]The number of participants who received RBC transfusions during the titration and evaluation periods were reported .
- Number of Participants With Marked Laboratory Abnormalities in Platelet, White Blood Cell Counts (WBC) and Red Blood Cells (RBC) [ Time Frame: Up to Week 53 ]Marked laboratory abnormalities were defined as those values that were outside the Roche marked abnormality reference range. These abnormality laboratory values were flagged as Low or High if they were below the lower limit or above the upper limit of Roche marked abnormality reference range, respectively. The marked abnormality reference range for Platelet was 100-550x10^9/Litre [L], for WBC was 3.0-18.0.0x10^9/L, and for RBC was 3.80-6.10x10^12/L.
- Number of Participants With Marked Laboratory Abnormalities for Blood Chemistry and Electrolytes [ Time Frame: Up to Week 53 ]Marked laboratory abnormalities were defined as those values that were outside the Roche marked abnormality reference range. These abnormality laboratory values were flagged as Low or High if they were below the lower limit or above the upper limit of Roche marked abnormality reference range, respectively. The marked abnormality reference range for aspartate aminotransferase (AST) was 0-80 (unit per litre [U/L]), alanine aminotransferase (ALT) 0-110 U/L, alkaline phosphatase (ALP) 0-220 U/L, albumin >=30.0 gram/litre (g/L), glucose in non-diabetics 2.80-11.10 (millimol/litre [mmol/L]); potassium 2.90-5.80 mmol/L, and phosphorus 0.75-1.60 mmol/L
- Mean Change in Blood Pressure From Baseline at Week 36 and Week 52 [ Time Frame: Baseline, Week 36 and Week 52 ]Blood pressure was measured by manual assessment or automated reading throughout the entire study for every participant. Blood pressure was taken in the sitting position after at least 5 minutes rest. An appropriate -sized cuff was used and both systolic (SBP) and diastolic (DBP) blood pressures were recorded before dialysis (BD) and after dialysis (AD).
- Mean Change in Pulse Rate (Sitting) From Baseline at Week 36 and Week 52 [ Time Frame: Baseline, Week 36 and Week 52 ]Change in pulse rate (beats per minute [bpm]) from baseline values includes only those participants with both a baseline value and a value for specified time period.
- Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs) and Death [ Time Frame: Upto Week 53 ]An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is a significant medical event in the investigator's judgment or requires intervention to prevent one or other of these outcomes. Overall deaths occurred in the study were reported.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00077610
Show 99 Study Locations
|Study Director:||Clinical Trials||Hoffmann-La Roche|